SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
(Amendment No. 2)*
Under the Securities Exchange Act of 1934
|Milestone Pharmaceuticals, Inc.|
|(Name of Issuer)|
|Common Shares, no par value per share|
|(Title of Class of Securities)|
|December 31, 2022|
|(Date of Event Which Requires Filing of this Statement)|
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
x Rule 13d-1(b)
o Rule 13d-1(c)
o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|CUSIP No. 59935V107||SCHEDULE 13G||Page 2 of 6 Pages|
NAME OF REPORTING PERSONS
OrbiMed Capital LLC
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
SEC USE ONLY
CITIZENSHIP OR PLACE OF ORGANIZATION
SOLE VOTING POWER
SHARED VOTING POWER
SOLE DISPOSITIVE POWER
SHARED DISPOSITIVE POWER
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
TYPE OF REPORTING PERSON
|CUSIP No. 59935V107||SCHEDULE 13G||Page 3 of 6 Pages|
|Item 1.||(a) Name of Issuer:|
Milestone Pharmaceuticals, Inc.
|(b) Address of Issuer’s Principal Executive Offices:|
1111 Dr. Frederik-Philips Boulevard
Montréal, Québec, Canada H4M 2X6
|Item 2.||(a) Name of Person Filing:|
OrbiMed Capital LLC
|(b) Address of Principal Business Office:|
601 Lexington Avenue, 54th Floor
New York, NY 10022
Please refer to Item 4 on the cover page for the Reporting Person.
|(d) Title of Class of Securities:|
Common Shares, no par value per share
|(e) CUSIP No.:|
|CUSIP No. 59935V107||SCHEDULE 13G||Page 4 of 6 Pages|
OrbiMed Capital LLC (“Capital”) is an investment advisor in accordance with ss.240.13d-1(b)(1)(ii)(E).
|CUSIP No. 59935V107||SCHEDULE 13G||Page 5 of 6 Pages|
Item 4. Ownership:
Information with respect to the Reporting Person’s ownership as of December 31, 2021 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Item 8. Identification and Classification of Members of the Group.
Item 9. Notice of Dissolution of Group.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|CUSIP No. 59935V107||SCHEDULE 13G||Page 6 of 6 Pages|
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2023
|OrbiMed Capital LLC|
|By:||/s/ Carl L. Gordon|
|Name:||Carl L. Gordon|